PE Hub has rounded up six deals going back to early January involving companies in the oncology segment, starting with the ...

IDRX-42 has the unique ability to identify all clinically significant KIT mutations present in GIST. IDRx is developing an experimental drug for the treatment of gastrointestinal stromal tumors, soft ...

We plan to advance IDRX-42 for second line treatment of gastrointestinal stromal tumours, where there are no approved treatments to effectively address all resistance mutations, and accelerate ...

IDRX-42 has received Fast Track designation by the U.S. FDA for the treatment of GIST after disease progression on or intolerance to imatinib and Orphan Drug designations for the treatment of GIST.

Today, GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $74.88 billion and impressive gross profit margins of 71.81%, announced the completion of its ...

IDRx specializes in developing precision therapies for gastrointestinal stromal tumors (GIST), a type of cancer originating in the gastrointestinal tract. This move includes the procurement of IDRX-42 ...

GSK will be responsible for success-based milestone payments, as well as tiered royalties for IDRX-42 owned to Darmstadt, Germany-based pharmaceutical firm Merck KGaA. GSK Senior Vice President Hesham ...

IDRX-42 has received Fast Track designation by the U.S. FDA for the treatment of GIST after disease progression on or intolerance to imatinib and Orphan Drug designations for the treatment of GIST.

IDRX-42 is a highly selective, investigational small molecule TKI designed to target all key KIT mutations in GIST. The U.S. Food and Drug Administration (FDA) has granted IDRX-42 Fast Track ...